Health Compiler Integrates with Mark Cuban Cost Plus Drug Company to Surface Real Drug Prices at the Point of Care

Health Compiler has integrated with Mark Cuban Cost Plus Drug Company. Cost Plus cash pricing now flows directly into the Health Compiler platform, where it appears alongside plan cost at the points where prescribing and payment decisions are made.

Cost Plus Drugs cash pricing now appears inside Health Compiler: while a prescription is being written, during employer claims review, and the moment a patient asks what a fill will cost.

A concrete example: atorvastatin 20mg, a 30 day supply, is priced at roughly $10 in cash through Cost Plus Drugs, including dispensing and shipping. A health plan may pay closer to $45 for the same fill. Health Compiler now puts both figures in front of the clinician, the employer and the patient, at the moment each of them needs it.

Where the pricing appears

Cost Plus publishes its full price list openly, along with the formula behind it: the cost of the medication, a fixed markup, a pharmacy fee, and shipping. Health Compiler takes that pricing and places it inside three existing workflows:

• In the exam room: Cash pricing appears while the prescription is still open on screen. Where a generic equivalent exists, it is surfaced as an explicit option, so the clinician can weigh cost alongside the clinical decision.
• In claims review: Employer pharmacy claims are priced against Cost Plus data automatically, so a benefits team sees drug-level cost comparisons in the same view as the rest of their spend.
• In the patient conversation: When a member asks what a medication will cost, the platform answers with both numbers and a direct link to purchase.

What the integration unlocks

Cost Plus Drugs remains the source of truth

Health Compiler does not resell medication, hold inventory or set prices. Cost Plus Drugs publishes the price. Health Compiler surfaces it in context and links back to costplusdrugs.com for fulfillment. Pricing is retrieved directly from Cost Plus and refreshed on a rolling basis, so quoted figures reflect current cost.

One point worth stating plainly: a cash purchase made outside the plan generally does not accrue toward a member's deductible. For members on low cost maintenance generics who are unlikely to reach their deductible in a given year, cash pricing is usually the better economic choice. For members with high annual utilization, the tradeoff deserves a real conversation. Health Compiler surfaces the comparison and the caveat together, and leaves the decision with the member and their clinician.

Who it is built for

• Self-funded employers and their advisors get drug level detail on pharmacy spend, in the same platform that already carries their claims, clinical and outcomes data.
• Direct Primary Care practices get a natural extension of a model they already run. DPC physicians control the prescribing decision and already work in a transparent pricing relationship with their patients. Cash drug pricing extends that conversation into one of the largest recurring out-of-pocket costs those patients carry.

What is next

Health Compiler is expanding drug level matching to capture a broader range of available generics, with particular focus on small molecule specialty generics and biosimilars, where the spread between plan cost and cash price tends to be widest.